Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Alan D. Feiger"'
Publikováno v:
The Journal of Clinical Psychiatry. 67:1354-1361
Objective: This study investigated the efficacy, safety, and tolerability of the selegiline transdermal system (STS) administered in a dose range of 6 mg/24 hours to 12 mg/24 hours for treating major depressive disorder (MDD). Method: Patients meetin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::401157e8f888dcd5afd1943986c63f0a
https://doi.org/10.4088/jcp.v67n0905
https://doi.org/10.4088/jcp.v67n0905
Autor:
Kenneth R. Evans, David J. DeBrota, Joshua D. Lipsitz, Kenneth A. Kobak, Kenneth O. Cogger, Alan D. Feiger, William Z. Potter, Nina Engelhardt, Dawn Sikich
Publikováno v:
Journal of Clinical Psychopharmacology. 26:71-74
Objective: The quality of clinical interviews conducted in industry-sponsored clinical drug trials is an important but frequently overlooked variable that may influence the outcome of a study. We evaluated the quality of Hamilton Rating Scale for Dep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::74c5363ac8a6bb587e2e2004cfb632bb
https://doi.org/10.1097/01.jcp.0000194621.61868.7c
https://doi.org/10.1097/01.jcp.0000194621.61868.7c
Publikováno v:
Psychiatry Research. 127:147-155
Previous studies of rater performance and interrater reliability have used passive scoring tasks such as rating patients from a videotaped interview. Little is known, however, about how well raters conduct assessments on real patients or how reliably
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::774fd8d274ed6f069b4dafd53b9c674e
https://doi.org/10.1016/j.psychres.2004.03.001
https://doi.org/10.1016/j.psychres.2004.03.001
Publikováno v:
International Clinical Psychopharmacology. 18:203-210
The aim of this study was to examine response and remission rates in outpatients treated with sertraline or fluoxetine who were suffering from two depression subtypes: anxious-depression and severe depression. Data were pooled from five double-blind
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::19b3a700556028e9dfdb44ab026d585d
https://doi.org/10.1097/00004850-200307000-00002
https://doi.org/10.1097/00004850-200307000-00002
Autor:
Alan D. Feiger, Ward T. Smith, Jon F. Heiser, Ram K. Shrivastava, Michael Gibertini, J M A Sitsen, Kenneth J. Weiss
Publikováno v:
The Journal of Clinical Psychiatry. 64:243-249
OBJECTIVE To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder. METHOD Patients aged 18 to 70 years were eligible if they sati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9d05bb9f524d07a688215521aa1ffcce
https://doi.org/10.4088/jcp.v64n0304
https://doi.org/10.4088/jcp.v64n0304
Autor:
Alan D Feiger, Richard L Rudolph
Publikováno v:
Journal of Affective Disorders. 56:171-181
We compared the efficacy and tolerability of venlafaxine XR with that of fluoxetine in a multicenter, randomized, double-blind, placebo-controlled study in depressed outpatients.Outpatients, 18 years and older, who met DSM-IV criteria for major depre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c77cc05fa5e793f3884db04455df58b
https://doi.org/10.1016/s0165-0327(99)00067-1
https://doi.org/10.1016/s0165-0327(99)00067-1
Autor:
Alan D, Feiger, Jon F, Heiser, Ram K, Shrivastava, Kenneth J, Weiss, Ward T, Smith, J M A, Sitsen, Michael, Gibertini
Publikováno v:
The Journal of clinical psychiatry. 64(3)
To assess the efficacy and tolerability of the 5-HT(1A) agonist gepirone in extended-release formulation (gepirone-ER) versus placebo in patients with major depressive disorder.Patients aged 18 to 70 years were eligible if they satisfied DSM-IV crite
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7323cf4ceeb9d7ee11bd93cb65f56c9e
https://pubmed.ncbi.nlm.nih.gov/12716264
https://pubmed.ncbi.nlm.nih.gov/12716264
Autor:
Charles S. Wilcox, Stephen Kaplita, Douglas L. Roberts, Robert J. Bielski, Donald G. Archibald, Madhukar H. Trivedi, James Bremner, Robert D. McQuade, Alan D. Feiger, Terry T. Kensler, Jon F. Heiser
Publikováno v:
International clinical psychopharmacology. 14(1)
The efficacy of nefazodone in prevention of relapse of depression was evaluated in a 36-week double-blind, placebo-substitution, continuation treatment trial. After 16 weeks of acute, single-blind treatment with nefazodone, 131 patients responding to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::532aa995429df6783e087260dec60fed
https://pubmed.ncbi.nlm.nih.gov/10221638
https://pubmed.ncbi.nlm.nih.gov/10221638
Autor:
Nina Engelhardt, Joshua D. Lipsitz, David J. DeBrota, William Z. Potter, Kenneth A. Kobak, Kenneth O. Cogger, Dawn Sikich, Kenneth R. Evans, Alan D. Feiger
Publikováno v:
Journal of Clinical Psychopharmacology. 27:116-117
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::99ff472c76890deab1db6f0fc651dae3
https://doi.org/10.1097/jcp.0b013e31802f0f08
https://doi.org/10.1097/jcp.0b013e31802f0f08
Autor:
Alan D. Feiger, Ari Kiev
Publikováno v:
The Journal of clinical psychiatry. 58(4)
Background : Fluvoxamine and paroxetine, both serotonin selective reuptake inhibitors (SSRIs), were compared at two centers in a 7-week double-blind study in outpatients with major depression, diagnosed by DSM-III-R criteria. Method: Sixty patients w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6f3547dacd5280f7fde4dce4a1c461a
https://pubmed.ncbi.nlm.nih.gov/9164424
https://pubmed.ncbi.nlm.nih.gov/9164424